繁體
简体中文
繁體中文

CombiMatrix Corp. CBMXW

已收盤 10-08 16:00:00 美东时间

2.50

0.000

0.00%

华盛通華盛通
立即下載
  • 最 高--
  • 今 開--
  • 成交量 0股
  • 最 低 --
  • 昨 收 2.50
  • 總市值 1840.00万
  • 52周最高 3.00
  • 市盈率 --
  • 換手率 0.00%
  • 52周最低 0.62
  • 委 比 0.00%
  • 總股本 736.00万
  • 歷史最高 3.00
  • 量 比 0
  • 振 幅 0.00%
  • 歷史最低 0.62
  • 每 手 1
  • 風險率

個股概要

財務分析

公司資料

相關新聞

分紅派息

  • 分時圖
  • 日k
  • 周k
  • 月k

相關新聞

更多
  • Mainz Biomed Announces Registration of ColoAlert in the United Kingdom

    Mainz Biomed's ColoAlert®, a non-invasive DNA-based colorectal cancer screening test, has been officially registered with the UK's MHRA and authorized for marketing. This milestone, achieved through a partnership with EDX Medical Group, aims to increase accessibility and participation in CRC screening, addressing the UK's fourth most common cancer. ColoAlert detects DNA biomarkers in stool samples, complementing existing screening programs and of...

    09-02 12:01

  • Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

    Biomea Fusion announced new data on icovamenib, an oral menin inhibitor, at ADA 2025. Preclinical studies show icovamenib enhances glycemic control and weight loss when combined with low-dose semaglutide, while preserving lean mass. It also rescues human myotube atrophy ex vivo. In the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted HbA1c reduction and a 55% increase in C-peptide at Week 26, demonstrating durable effects ...

    06-23 11:00